Open AccessLY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas
Author(s) -
D. J. Flournoy,
Fred A. Perryman
Publication year - 1979
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.16.5.641
Subject(s) - carbenicillin , ticarcillin , microbiology and biotechnology , enterobacter , proteus vulgaris , klebsiella , providencia , cefoxitin , tobramycin , serratia , proteus , klebsiella pneumoniae , piperacillin , amikacin , serratia marcescens , gentamicin , biology , antimicrobial , pseudomonas aeruginosa , pseudomonas , antibiotics , imipenem , antibiotic resistance , bacteria , escherichia coli , staphylococcus aureus , biochemistry , genetics , gene
One hundred eight clinical isolates of Proteus, Klebsiella, Serratia, and Pseudomonas spp. were tested in vitro against LY127935, cefamandole, cefoxitin, ticarcillin, carbenicillin, gentamicin, tobramycin, and amikacin by broth microdilution. The activities of LY127935 were greater than or equal to those of the other antimicrobial agents against Proteus vulgaris, Klebsiella pneumoniae, and Serratia marcescens. Inhibitions were greatest, however, for ticarcillin and carbenicillin versus Proteus morganii and gentamicin versus Pseudomonas aeruginosa.